PDP Access Steering Committee

Contact Us


Positive phase 1 results for iOWH032


An important milestone reached in our diarrheal disease program with the completion of two phase 1 clinical studies for iOWH032—our investigational new drug to treat acute secretory diarrhea caused by diseases such as cholera.

PATH’s drug development program announces positive phase 1 results for its anti-diarrheal medication

Link to press release